Immunotherapy for renal cell carcinoma (Q35157638)

6 August 2017

1 reference

title

Immunotherapy for renal cell carcinoma. (English)

1 reference

6 August 2017

1 reference

Ivar Bleumer

1

1 reference

6 August 2017

Egbert Oosterwijk

series ordinal

2

1 reference

6 August 2017

Pieter De Mulder

series ordinal

3

1 reference

6 August 2017

Peter F A Mulders

series ordinal

4

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

6 August 2017

1 reference

6 August 2017

44

1 reference

6 August 2017

1

1 reference

6 August 2017

65-75

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

6 August 2017

1 reference

7 January 2021

Time trends in the incidence of renal carcinoma: analysis of Connecticut Tumor Registry data, 1935-1989.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Renal cell carcinoma: incidental diagnosis and natural history: review of 235 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

The changing natural history of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Prognostic significance of morphologic parameters in renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Long-term results of resection of renal cell cancer with extension into inferior vena cava

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Microscopic vascular invasion is the most relevant prognosticator after radical nephrectomy for clinically nonmetastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Multidrug resistance (mdr) genes in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Cancer immunoediting: from immunosurveillance to tumor escape

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Ig-binding receptors on human NK cells as effector and regulatory surface molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Adjuvant interferon-alpha in malignant melanoma: current status

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Interaction of retinoic acid and interferon in renal cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

A dual anti-tumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

The impact of interleukin-2 on survival in renal cancer: a multivariate analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Interferon-alpha and survival in renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Haemopoietic stem-cell transplantation: recent progress and future promise

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

The dendritic cell system and its role in immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Role of annexins in endocytosis of antigens in immature human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Internalization and degradation of macrophage Fc receptors during receptor-mediated phagocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries?

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Rituximab: perspective on single agent experience, and future directions in combination trials

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Clinical trials of Herceptin(trastuzumab).

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0302-2838%2803%2900191-X

7 January 2021

10.1016/S0302-2838(03)00191-X

Identifiers

DOI

1 reference

6 August 2017

1 reference